Cargando…
Cardiotoxicity Related to Immune Checkpoint Inhibitors: A Real-World Retrospective Analysis
BACKGROUND: Cardiotoxicity related to immune checkpoint inhibitors (ICIs) is a rare but potentially lethal. In ICI-associated adverse events, evidence of cardiotoxicity and clinical predictive factors related to ICI is lacking. Here, we aim to assess the incidence and predictive factors of cardiotox...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9193585/ https://www.ncbi.nlm.nih.gov/pubmed/35711379 http://dx.doi.org/10.3389/fcvm.2022.838488 |
_version_ | 1784726499451994112 |
---|---|
author | She, Jianqing Liu, Hui Wu, Haoyu Tuerhongjiang, Gulinigaer Zheng, Tao Bai, Ling |
author_facet | She, Jianqing Liu, Hui Wu, Haoyu Tuerhongjiang, Gulinigaer Zheng, Tao Bai, Ling |
author_sort | She, Jianqing |
collection | PubMed |
description | BACKGROUND: Cardiotoxicity related to immune checkpoint inhibitors (ICIs) is a rare but potentially lethal. In ICI-associated adverse events, evidence of cardiotoxicity and clinical predictive factors related to ICI is lacking. Here, we aim to assess the incidence and predictive factors of cardiotoxicity related to ICIs in real-world practice. OBJECTIVE: We retrospectively analyzed consecutive patients who received PD-1 or PD-L1 at the First Affiliated Hospital of Xi'an Jiaotong University. Clinical characteristics and cardiac lesion markers were collected both at baseline and during longitudinal follow-up from the Biobank database. Follow-up CKMB and NT-proBNP levels and ratios were then evaluated. RESULTS: A total of 2,304 patients with either PD-1 or PDL-1 utilization between August 2018 and April 2021 were collected. The average age was 59.44 ± 11.45 among PD-1 inhibitor utilizer and 58.97 ± 12.16 among PDL-1 inhibitor utilizer. The baseline creatine kinase isoenzyme MB (CKMB) levels were 17 ± 19 U/L in PD-1 inhibitor users and 17 ± 23 U/L in PDL-1 inhibitor users. Majority of patients were male, with advanced stage cancer, and received ICIs as second-line therapy. The longitudinal change of cardiac enzymes and NT-pro BNP were collected. Cardiac lesion as defined by three times increase of CKMB happens in only minority of patients receiving ICIs therapy. It is also identified that increased CKMB happened in PD-1 inhibitor groups, but not PDL-1 inhibitor groups. CONCLUSION: We evaluated the profile of cardiotoxicities caused by ICIs based on real-world experience. The cardiac lesion markers are generally unaltered, but it appears that the increased CKMB happened in PD-1 inhibitor groups, but not PDL-1 inhibitor groups. |
format | Online Article Text |
id | pubmed-9193585 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91935852022-06-15 Cardiotoxicity Related to Immune Checkpoint Inhibitors: A Real-World Retrospective Analysis She, Jianqing Liu, Hui Wu, Haoyu Tuerhongjiang, Gulinigaer Zheng, Tao Bai, Ling Front Cardiovasc Med Cardiovascular Medicine BACKGROUND: Cardiotoxicity related to immune checkpoint inhibitors (ICIs) is a rare but potentially lethal. In ICI-associated adverse events, evidence of cardiotoxicity and clinical predictive factors related to ICI is lacking. Here, we aim to assess the incidence and predictive factors of cardiotoxicity related to ICIs in real-world practice. OBJECTIVE: We retrospectively analyzed consecutive patients who received PD-1 or PD-L1 at the First Affiliated Hospital of Xi'an Jiaotong University. Clinical characteristics and cardiac lesion markers were collected both at baseline and during longitudinal follow-up from the Biobank database. Follow-up CKMB and NT-proBNP levels and ratios were then evaluated. RESULTS: A total of 2,304 patients with either PD-1 or PDL-1 utilization between August 2018 and April 2021 were collected. The average age was 59.44 ± 11.45 among PD-1 inhibitor utilizer and 58.97 ± 12.16 among PDL-1 inhibitor utilizer. The baseline creatine kinase isoenzyme MB (CKMB) levels were 17 ± 19 U/L in PD-1 inhibitor users and 17 ± 23 U/L in PDL-1 inhibitor users. Majority of patients were male, with advanced stage cancer, and received ICIs as second-line therapy. The longitudinal change of cardiac enzymes and NT-pro BNP were collected. Cardiac lesion as defined by three times increase of CKMB happens in only minority of patients receiving ICIs therapy. It is also identified that increased CKMB happened in PD-1 inhibitor groups, but not PDL-1 inhibitor groups. CONCLUSION: We evaluated the profile of cardiotoxicities caused by ICIs based on real-world experience. The cardiac lesion markers are generally unaltered, but it appears that the increased CKMB happened in PD-1 inhibitor groups, but not PDL-1 inhibitor groups. Frontiers Media S.A. 2022-05-31 /pmc/articles/PMC9193585/ /pubmed/35711379 http://dx.doi.org/10.3389/fcvm.2022.838488 Text en Copyright © 2022 She, Liu, Wu, Tuerhongjiang, Zheng and Bai. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cardiovascular Medicine She, Jianqing Liu, Hui Wu, Haoyu Tuerhongjiang, Gulinigaer Zheng, Tao Bai, Ling Cardiotoxicity Related to Immune Checkpoint Inhibitors: A Real-World Retrospective Analysis |
title | Cardiotoxicity Related to Immune Checkpoint Inhibitors: A Real-World Retrospective Analysis |
title_full | Cardiotoxicity Related to Immune Checkpoint Inhibitors: A Real-World Retrospective Analysis |
title_fullStr | Cardiotoxicity Related to Immune Checkpoint Inhibitors: A Real-World Retrospective Analysis |
title_full_unstemmed | Cardiotoxicity Related to Immune Checkpoint Inhibitors: A Real-World Retrospective Analysis |
title_short | Cardiotoxicity Related to Immune Checkpoint Inhibitors: A Real-World Retrospective Analysis |
title_sort | cardiotoxicity related to immune checkpoint inhibitors: a real-world retrospective analysis |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9193585/ https://www.ncbi.nlm.nih.gov/pubmed/35711379 http://dx.doi.org/10.3389/fcvm.2022.838488 |
work_keys_str_mv | AT shejianqing cardiotoxicityrelatedtoimmunecheckpointinhibitorsarealworldretrospectiveanalysis AT liuhui cardiotoxicityrelatedtoimmunecheckpointinhibitorsarealworldretrospectiveanalysis AT wuhaoyu cardiotoxicityrelatedtoimmunecheckpointinhibitorsarealworldretrospectiveanalysis AT tuerhongjianggulinigaer cardiotoxicityrelatedtoimmunecheckpointinhibitorsarealworldretrospectiveanalysis AT zhengtao cardiotoxicityrelatedtoimmunecheckpointinhibitorsarealworldretrospectiveanalysis AT bailing cardiotoxicityrelatedtoimmunecheckpointinhibitorsarealworldretrospectiveanalysis |